[87]
Apotex alleges that each claim of the '080 patent is anticipated by the prior disclosure of ofloxacin. Justice Hughes rejected a similar argument in the
Novopharm
Trial and was upheld by the Federal Court of Appeal. Apotex relies only on the '840 Patent for this assertion. The relevant date for assessing anticipation is June 19, 1984, two years prior to the Canadian filing date. (NOA at p. 31; Klibanov Affidavit Ex. B, AR, v. 12, Tab 17, p. 3519;
Patent Act
, s. 27(1),
Novopharm
Trial, above at para. 108.)
Legal principles
The alleged anticipatory disclosure must, on its own, provide directions that would inevitably result in the invention claimed